Germany is one of the world’s most advanced countries when it comes to Alzheimer’s disease research and care. It benefits from a dense network of around 160 memory clinics, an ambitious National Dementia Strategy, and a universal health insurance system that covers most standard diagnostic and treatment costs. German researchers are at the frontier of early detection, pioneering everything from blood-based biomarker tests to smartphone memory assessments
And yet, even here, the system struggles with one of the most persistent challenges in Alzheimer’s care: people are not being diagnosed early enough. As explored in the Germany country profile on the Atlas, the average wait from a patient’s first concern to a completed diagnostic evaluation was estimated at 29 months in 2024, and could rise to as long as 65 months by 2028 if specialist capacity is not significantly expanded.
This is exactly the gap that ALFie – Alzheimer – Leitliniengerechte Früherkennung in Köln (Alzheimer – Guideline-Based Early Detection in Cologne) – was built to address.
ALFie is a pioneering healthcare initiative based in Cologne, Germany, designed to transform how Alzheimer’s disease is detected and managed in real-world clinical practice. At its heart, ALFie establishes a standardized, evidence-based care pathway grounded in Germany’s S3 clinical guideline for dementia – the highest level of evidence-based clinical guidance available. But ALFie is more than a clinical protocol. It has evolved into a digital platform – ALFie digital – that connects every stakeholder in the Alzheimer’s care journey: general practitioners, neurologists, memory clinics, counselling centres, laboratories, social services, and most importantly, patients and their families. The platform is available as an app on both the Google Play Store and the Apple App Store, making it accessible to professionals and caregivers alike. The initiative is led by a distinguished team of experts, including Prof. Dr. Frank Jessen and Prof. Dr. Özgür Onur from University Hospital Cologne, and Prof. Dr. Gereon Nelles from Neuromed Campus. It is enabled by Lilly Deutschland GmbH, in cooperation with Gesundheitsregion KölnBonn e.V.
Early detection opens doors. It allows individuals and families to plan ahead, access support services sooner, participate in clinical trials, and – as disease-modifying treatments continue to emerge – potentially benefit from therapies that are most effective in the earliest stages of disease.
The challenge has always been structural. The pathway from a patient first raising concerns with their GP to receiving a confirmed diagnosis is often fragmented, slow, and inconsistent. Referrals get lost. Waiting times stretch. Families are left navigating a complex system without a map. ALFie directly addresses this. By creating a shared digital infrastructure that keeps all care partners connected and informed, it reduces delays, eliminates duplication, and ensures that the right expertise reaches the patient at the right time.
The arrival of the first amyloid-targeting therapies in Germany has changed the stakes of the diagnostic wait. These treatments are specifically indicated for those in the earliest stages of the disease – the “Mild Cognitive Impairment” (MCI) and mild dementia phases. In the old, fragmented system, a 29-month wait meant that many patients would have progressed past the “eligibility window” by the time they received a confirmed diagnosis. ALFie effectively acts as a gatekeeper for innovation. By streamlining the path to advanced diagnostics like biomarker testing and PET scans, it ensures that patients in Cologne have a fighting chance to access these new therapies while they are still eligible to benefit from them.
While ALFie is currently a “Cologne Project,” its implications are national. By proving that a digital, guideline-compliant bridge can be built between the GP’s office and the specialized clinic, the team led by Dr. Jessen and Dr. Onur is creating a blueprint for the rest of Germany.
As we look ahead through 2026, the success of ALFie won’t just be measured in data points or app downloads, but in the months and years of quality life returned to families. In a field where we have spent decades feeling powerless, ALFie is a reminder that while we wait for a cure, we can – and must – fix the care.